Bayer Backs Hot Flashes Drug For Blockbuster Status
As German Major Posts Decent Q3 Figures
Executive Summary
The menopause drug elinzanetant, which has just gone into Phase III, has joined Kerendia, Verquvo and Nubeqa as a candidate that Bayer believes has a peak sales potential of more than €1bn.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Pfizer’s "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.
GSK Shoulder-To-Shoulder With CureVac Over COVID-19 Vaccine U-Turn
The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.
Bayer Backs Kerendia To Be A Blockbuster
Just approved In US for chronic kidney disease in patients with type 2 diabetes, Kerendia is going to be an important new treatment option, according to Bayer pharma head Stefan Oelrich, who was speaking as the Leverkusen-headquartered group unveiled a decent set of sales figures for the second quarter.